Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥16.30 |
52 Week High | CN¥25.50 |
52 Week Low | CN¥14.81 |
Beta | 0.53 |
11 Month Change | -0.67% |
3 Month Change | -3.72% |
1 Year Change | -32.51% |
33 Year Change | -40.70% |
5 Year Change | 34.38% |
Change since IPO | 72.03% |
Recent News & Updates
Shareholder Returns
002932 | CN Medical Equipment | CN Market | |
---|---|---|---|
7D | 4.3% | 0.8% | 5.4% |
1Y | -32.5% | -20.2% | -16.2% |
Return vs Industry: 002932 underperformed the CN Medical Equipment industry which returned -20.2% over the past year.
Return vs Market: 002932 underperformed the CN Market which returned -16.2% over the past year.
Price Volatility
002932 volatility | |
---|---|
002932 Average Weekly Movement | 4.6% |
Medical Equipment Industry Average Movement | 5.3% |
Market Average Movement | 5.4% |
10% most volatile stocks in CN Market | 8.4% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 002932 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002932's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 1,547 | Chen Li Li | www.mdeasydiagnosis.com |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Fundamentals Summary
002932 fundamental statistics | |
---|---|
Market cap | CN¥3.56b |
Earnings (TTM) | CN¥27.52m |
Revenue (TTM) | CN¥366.25m |
132.8x
P/E Ratio10.0x
P/S RatioIs 002932 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
002932 income statement (TTM) | |
---|---|
Revenue | CN¥366.25m |
Cost of Revenue | CN¥97.16m |
Gross Profit | CN¥269.09m |
Other Expenses | CN¥241.57m |
Earnings | CN¥27.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.12 |
Gross Margin | 73.47% |
Net Profit Margin | 7.51% |
Debt/Equity Ratio | 0.05% |
How did 002932 perform over the long term?
See historical performance and comparison